April 27, 2018 | Daily JAM, MRK, Stock Alerts |
News out of the imuno-oncology sector of the biotech world has hit stocks in my portfolios such as Incyte (INCY) and Nektar Therapeutics (NKTR) hard. But, I'd argue that it has left Keytruda and its owner Merck (MRK) in a measurably stronger position in the market for...
